"Highlights
Lipid nanoparticles (LNPs) probably have a broad distribution in human tissues/organs; they may also (along with the packaged mRNA) exert a proinflammatory action.
COVID-19 mRNA vaccines encode a transmembrane SARS-CoV-2spike(S) protein; however, shedding of the antigen and/or related peptide fragments into the circulation may occur...
[P]rospective pharmacovigilance and long-term monitoring of vaccinated recipients should be a public health priority...
Anti-SARS-CoV-2 mRNA vaccines and their reported adverse effects
... Although rare, AEs include serious clinical manifestations such as acute myocardial infarction, Bell’s palsy, cerebral venous sinus thrombosis, Guillain–Barré syndrome, myocarditis/pericarditis (mostly in younger ages), pulmonary embolism, stroke, thrombosis with thrombocytopenia syndrome, lymphadenopathy, appendicitis, herpes zoster reactivation, neurological complications, and autoimmunity (e.g., autoimmune hepatitis and autoimmune peripheral neuropathies...
There is also evidence that ionizable lipids within LNPs can trigger proinflammatory responses by activating Toll-like receptors (TLRs). A recent report showed that LNPs used in preclinical nucleoside-modified mRNA vaccine studies are (independently of the delivery route) highly inflamatory in mice, as evidenced by excessive neutrophil infiltration activation of diverse inflammatory pathways, and production of various inflammatory cytokines and chemokines. . .
Concluding remarks . . . Finally, as we essentially do not know for how long and at what concentration the LNPs and the antigen(s) remain in human tissues or the circulation of poor vaccine responders the elderly, or children (see Outstanding questions), and given the fact that cellular immunity likely persists despite reduced in vitro neutralizing titers... boosting doses should be delivered only where the benefit–risk profile is clearly established."
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.